IDWeek 2026: despite missing primary endpoint, LB6V shows promise in Lyme disease
At the IDWeek 2026 conference in Washington DC, Dr Paul Auwaerter, clinical director and Professor of Medicine at John Hopkins …
Post
-
-
Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal
Astellas Pharma has inked a billion-dollar licensing deal with Australian biotech, Audax Biosciences, which will see the company secure access …
-
Anthropic plots IPO amid ongoing foray into drug development
Artificial intelligence (AI) specialist Anthropic has detailed its plans to dive deeper into the world of drug discovery and development …
-
FDA grants orphan drug status to Octant’s OCT-980 for RP
The US Food and Drug Administration (FDA) has granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, …
-
Arrowhead gains UK marketing authorisation for Redemplo
Arrowhead Pharmaceuticals has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Redemplo (plozasiran) as …
-
Arrowhead gains UK marketing authorisation for Redemplo
Arrowhead Pharmaceuticals has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Redemplo (plozasiran) as …
-
ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial
At the 2026 European Society for Medical Oncology (ESMO) Congress, investigators presented interim data from the Phase III MOIO study, …
-
ESMO26: Intismeran sets new benchmark in adjuvant melanoma
At the 2026 European Society for Medical Oncology (ESMO) Congress, full results from Merck and Moderna’s Phase III INTerpath-001 trial …
-
ESMO26: KEYNOTE-C93 backs chemo-free Keytruda in dMMR endometrial cancer
Mismatch repair-deficient (dMMR) endometrial cancer is among the most immunotherapy-sensitive solid tumours. Yet first-line treatment typically pairs immunotherapy with carboplatin …
-
ESMO26: Sac-TMT sets survival benchmark in recurrent endometrial cancer
Following progression on platinum-based chemotherapy and immunotherapy, patients with advanced or recurrent endometrial cancer (EC) face limited treatment options. The …
-
Pfizer’s prostate cancer combo moves to earlier line on expanded US approval
The US Food and Drug Administration (FDA) has awarded a label expansion to Pfizer’s targeted oncology combination of Talzenna (talazoparib) …
-
Regeneron agrees to $270m extension to supply Ebola medicine in US
Regeneron Pharmaceuticals has agreed to a nearly $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government …
-
China’s NMPA accepts Innovent application for sintilimab combo
Innovent Biologics has received acceptance from China's National Medical Products Administration (NMPA) to review its sintilimab and Nolgileucel injection (GC101) …
-
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
Results of two Phase III trials, SANOVO and SAFFRON, with HUTCHMED and AstraZeneca’s Orpathys (savolitinib) were presented recently at the …
-
Transitioning from lab bench to GMP: What research scientists should know about manual aseptic filling
Many breakthrough therapies originate in research labs: academic institutions, biotech startups, and translational centers. The research-grade environments in which these …
